Therefore, when the GCN5 inhibitor MB-3 is administered upstream of glutamine metabolism, the combination of anti-PD-1 antibodies and immune checkpoint blockade results in the elimination of tumor immune evasion and the enhancement of antitumor efficacy. Here, PDCD1 is linked to neoplasm.